Charles River Laboratories (CRL) - Total Assets
Based on the latest financial reports, Charles River Laboratories (CRL) holds total assets worth $7.53 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Charles River Laboratories - Total Assets Trend (1998–2025)
This chart illustrates how Charles River Laboratories's total assets have evolved over time, based on quarterly financial data. Also see how much is Charles River Laboratories worth for the company's overall valuation and market capitalisation.
Charles River Laboratories - Asset Composition Analysis
Current Asset Composition (December 2025)
Charles River Laboratories's total assets of $7.53 Billion consist of 20.3% current assets and 79.7% non-current assets. Review CRL total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $213.77 Million | 3.0% |
| Accounts Receivable | $708.86 Million | 9.9% |
| Inventory | $299.10 Million | 4.2% |
| Property, Plant & Equipment | $2.02 Billion | 28.3% |
| Intangible Assets | $340.00 Million | 4.8% |
| Goodwill | $2.76 Billion | 38.7% |
Asset Composition Trend (1998–2025)
This chart illustrates how Charles River Laboratories's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CRL live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Charles River Laboratories's current assets represent 20.3% of total assets in 2025, a decrease from 41.5% in 1998.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, down from 10.6% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 14.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 38.7% of total assets.
Charles River Laboratories Competitors by Total Assets
Key competitors of Charles River Laboratories based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩335.22 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €88.84 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Charles River Laboratories - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.36 | 1.40 |
| Quick Ratio | 1.04 | 1.10 | 1.22 |
| Cash Ratio | 0.00 | 0.17 | 0.22 |
| Working Capital | $394.36 Million | $389.42 Million | $395.29 Million |
Charles River Laboratories - Advanced Valuation Insights
This section examines the relationship between Charles River Laboratories's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.50 |
| Latest Market Cap to Assets Ratio | 1.79 |
| Asset Growth Rate (YoY) | -5.2% |
| Total Assets | $7.14 Billion |
| Market Capitalization | $12.77 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Charles River Laboratories's assets above their book value (1.79x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Charles River Laboratories's assets decreased by 5.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Charles River Laboratories (1998–2025)
The table below shows the annual total assets of Charles River Laboratories from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.14 Billion | -5.22% |
| 2024-12-31 | $7.53 Billion | -8.13% |
| 2023-12-31 | $8.20 Billion | +7.79% |
| 2022-12-31 | $7.60 Billion | +8.24% |
| 2021-12-31 | $7.02 Billion | +27.93% |
| 2020-12-31 | $5.49 Billion | +17.01% |
| 2019-12-31 | $4.69 Billion | +21.70% |
| 2018-12-31 | $3.86 Billion | +31.60% |
| 2017-12-31 | $2.93 Billion | +8.04% |
| 2016-12-31 | $2.71 Billion | +31.10% |
| 2015-12-31 | $2.07 Billion | +9.72% |
| 2014-12-31 | $1.89 Billion | +14.63% |
| 2013-12-31 | $1.64 Billion | +3.67% |
| 2012-12-31 | $1.59 Billion | +1.80% |
| 2011-12-31 | $1.56 Billion | -10.10% |
| 2010-12-31 | $1.73 Billion | -21.36% |
| 2009-12-31 | $2.20 Billion | +2.05% |
| 2008-12-31 | $2.16 Billion | -23.01% |
| 2007-12-31 | $2.81 Billion | +9.70% |
| 2006-12-31 | $2.56 Billion | +0.76% |
| 2005-12-31 | $2.54 Billion | -3.37% |
| 2004-12-31 | $2.63 Billion | +228.54% |
| 2003-12-31 | $799.55 Million | +14.00% |
| 2002-12-31 | $701.34 Million | +22.75% |
| 2001-12-31 | $571.36 Million | +39.15% |
| 2000-12-31 | $410.61 Million | +13.10% |
| 1999-12-31 | $363.06 Million | +54.98% |
| 1998-12-31 | $234.25 Million | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more